P. Sheppard, IL-28, IL-29 and their class II cytokine receptor IL-28R, Nature Immunology, vol.4, issue.1, pp.63-68, 2003.
DOI : 10.1038/ni873

S. V. Kotenko, IFN-??s mediate antiviral protection through a distinct class II cytokine receptor complex, Nature Immunology, vol.4, issue.1, pp.69-77, 2003.
DOI : 10.1038/ni875

. Ge, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance, Nature, vol.18, issue.7262, pp.399-401, 2009.
DOI : 10.1038/nature08309

. Thomson, Interleukin-28B Polymorphism Improves Viral Kinetics and Is the Strongest Pretreatment Predictor of Sustained Virologic Response in Genotype 1 Hepatitis C Virus, Gastroenterology, vol.139, issue.1, pp.120-129, 2010.
DOI : 10.1053/j.gastro.2010.04.013

. Mangia, An IL28B Polymorphism Determines Treatment Response of Hepatitis C Virus Genotype 2 or 3 Patients Who Do Not Achieve a Rapid Virologic Response, Gastroenterology, vol.139, issue.3, pp.821-827, 2010.
DOI : 10.1053/j.gastro.2010.05.079

E. Thervet, M. Loriot, and S. Barbier, Optimization of Initial Tacrolimus Dose Using Pharmacogenetic Testing, Clinical Pharmacology & Therapeutics, vol.87, issue.6, pp.721-726, 2010.
DOI : 10.1097/00007890-200212150-00002

E. Thervet, Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients12, Transplantation, vol.76, issue.8, pp.1233-1235, 2003.
DOI : 10.1097/01.TP.0000090753.99170.89

Y. Shi, Y. Li, J. Tang, J. Zhang, Y. Zou et al., Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients, Gene, vol.512, issue.2, pp.226-257, 2013.
DOI : 10.1016/j.gene.2012.10.048

N. Picard, K. Rouguieg-malki, N. Kamar, and L. Rostaing, CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients, Transplantation, vol.91, issue.6, pp.652-658, 2011.
DOI : 10.1097/TP.0b013e31820ae4ac

URL : https://hal.archives-ouvertes.fr/inserm-00542366

M. Wadelius, L. Chen, and J. Lindh, The largest prospective warfarin-treated cohort supports genetic forecasting, Blood, vol.113, issue.4, pp.784-792, 2009.
DOI : 10.1182/blood-2008-04-149070

. International-warfarin-pharmacogenetics-consortium, T. Klein, and R. Altman, Estimation of the warfarin dose with clinical and pharmacogenetic data, N. Engl. J. Med, vol.360, issue.8, pp.753-764, 2009.

U. Schwartz, M. Ritchie, and Y. Bradford, Genetic Determinants of Response to Warfarin During Initial Anticoagulation, Journal of Vascular Surgery, vol.47, issue.6, pp.999-1008, 2008.
DOI : 10.1016/j.jvs.2008.04.040

G. Aithal, C. Day, P. Kesteven, and A. Daly, Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications, The Lancet, vol.353, issue.9154, pp.717-719, 1999.
DOI : 10.1016/S0140-6736(98)04474-2

R. Van-schie, M. Wadelius, and F. Kamali, Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design, Pharmacogenomics, vol.10, issue.10, pp.1687-1695, 2009.
DOI : 10.2217/pgs.09.125

N. Picard, K. Rouguieg-malki, N. Kamar, and L. Rostaing, CYP3A5 Genotype Does Not Influence Everolimus In Vitro Metabolism and Clinical Pharmacokinetics in Renal Transplant Recipients, Transplantation, vol.91, issue.6, pp.652-658, 2011.
DOI : 10.1097/TP.0b013e31820ae4ac

URL : https://hal.archives-ouvertes.fr/inserm-00542366

B. Gage, Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.col Ther, 2008.

S. Rost, Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2, Nature, vol.427, issue.6974, pp.537-541, 2004.
DOI : 10.1038/nature02214

M. Rieder, A. Reiner, and B. Gage, Haplotypes on Transcriptional Regulation and Warfarin Dose, New England Journal of Medicine, vol.352, issue.22, pp.2285-2293, 2005.
DOI : 10.1056/NEJMoa044503

T. Li, C. Chang, D. Jin, P. Lin, A. Khvorova et al., Identification of the gene for vitamin K epoxide reductase, Nature, vol.427, issue.6974, pp.541-544, 2004.
DOI : 10.1038/nature02254

B. Gage, Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin.col Ther, 2008.

S. Rost, Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin, Thromb Haemost, 2005.

W. Evans, Preponderance of Thiopurine S-Methyltransferase Deficiency and Heterozygosity Among Patients Intolerant to Mercaptopurine or Azathioprine, Journal of Clinical Oncology, vol.19, issue.8, pp.2293-2301, 2001.
DOI : 10.1200/JCO.2001.19.8.2293

T. Adam-de-beaumais, Determinants of mercaptopurine toxicity in paediatric acute lymphoblastic leukemia maintenance therapy, British Journal of Clinical Pharmacology, vol.66, issue.4, pp.575-84, 2011.
DOI : 10.1111/j.1365-2125.2010.03867.x

M. Stanulla, Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia, JAMA Mar, vol.23293, issue.12, pp.1485-1494, 2005.

M. Niemi, Transporter Pharmacogenetics and Statin Toxicity, Clinical Pharmacology & Therapeutics, vol.278, issue.1, pp.130-133, 2010.
DOI : 10.1097/01.fpc.0000230422.50962.91

. Search-collaborative-group, E. Link, and S. Parish, SLCO1B1 variants and statin-induced myopathy ? a genomewide study, N. Engl. J. Med, vol.359, issue.8, pp.789-799, 2008.

M. Niemi, M. Pasanen, and P. Neuvonen, SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin, Clinical Pharmacology & Therapeutics, vol.80, issue.4, pp.356-366, 2006.
DOI : 10.1016/j.clpt.2006.06.010

R. Wilke, The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy, Clinical Pharmacology & Therapeutics, vol.378, issue.1, pp.112-119
DOI : 10.1038/clpt.2010.279

M. Pasanen, Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin, Clinical Pharmacology & Therapeutics, vol.382, issue.6, pp.726-733, 2007.
DOI : 10.1038/sj.clpt.6100220

. Modalités-de-prélèvement, Type de prélèvement : sang total sur tube EDTA (bouchon Violet) -Acheminement: délai maximum 48h à température ambiante, congelé si délai supérieur. -Consentement écrit signé du patient et du médecin prescripteur indispensable -Info cliniques : prescription médicale détaillée précisant le gène à génotyper

Y. Maruo, Prolonged Unconjugated Hyperbilirubinemia Associated With Breast Milk and Mutations of the Bilirubin Uridine Diphosphate- Glucuronosyltransferase Gene, Pediatrics, vol.106, issue.5, 2000.
DOI : 10.1542/peds.106.5.e59

S. Aono, Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet, Apr, vol.15345, issue.8955, pp.958-967, 1995.

J. Ritter, Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gene complex of a Crigler-Najjar type I patient., Journal of Clinical Investigation, vol.90, issue.1, pp.150-155, 1992.
DOI : 10.1172/JCI115829

M. Li, Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther, pp.1653-61, 2014.

G. Toffoli, The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer, Journal of Clinical Oncology, vol.24, issue.19, pp.3061-3069, 2006.
DOI : 10.1200/JCO.2005.05.5400

C. Eap, S. Bender, J. Sirot, E. Cucchia, G. Jonzier-perey et al., Non response to clozapine and ultrarapid CYP1A2 activity: clinical data and analysis of CYP1A2 gene, J Clin Psychopharmacol, 2004.

W. Cheng, T. Murhy, and M. Smith, Dose-dependent pharmacokinetics of caffeine in humans: Relevance as a test of quantitative liver function, Clinical Pharmacology and Therapeutics, vol.47, issue.4, pp.516-524, 1990.
DOI : 10.1038/clpt.1990.66

L. Becquemont, A. Alfirevic, U. Amstutz, H. Brauch, E. Jacqz-aigrain et al., Practical recommendations for pharmacogenomics-based prescription, ESF-UB Conference on Pharmacogenetics and Pharmacogenomics, pp.113-137, 2010.
DOI : 10.2217/pgs.10.147

A. Gaedigk, The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype, Clinical Pharmacology & Therapeutics, vol.38, issue.2, pp.234-276, 2008.
DOI : 10.1038/sj.clpt.6100406

W. Schroth, Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes, Journal of Clinical Oncology, vol.25, issue.33, pp.5187-93, 2007.
DOI : 10.1200/JCO.2007.12.2705

Q. Pei, Cytochrome P450 2D6*10 genotype affects the pharmacokinetics of dimemorfan in healthy Chinese subjects, European Journal of Drug Metabolism and Pharmacokinetics, vol.16, issue.914
DOI : 10.1007/s13318-014-0221-x

P. Pouyanne, F. Haramburu, J. Imbs, and B. Bégaud, Admissions to hospital caused by adverse drug reactions: cross sectional incidence study, BMJ, vol.320, issue.7241, p.1036, 2000.
DOI : 10.1136/bmj.320.7241.1036

E. Etude, Effets indésirables des médicaments: Incidence et risques, sur les hospitalisations liées à un effet indésirable médicamenteux, Coordination CRPV, vol.4, p.2012, 2007.

. Investigators, Genetic determinants of response to clopidogrel and cardiovascular events, N Engl J Med, 2009.

. Van-de-vijer, A Gene-Expression Signature as a Predictor of Survival in Breast Cancer, New England Journal of Medicine, vol.347, issue.25, pp.1999-2009, 2002.
DOI : 10.1056/NEJMoa021967

P. Carson, C. Flanagan, C. Ickes, and A. Alving, Enzymatic Deficiency in Primaquine-Sensitive Erythrocytes, Science, vol.124, issue.3220, pp.484-485, 1956.
DOI : 10.1126/science.124.3220.484-a

F. Vogel, Moderne Probleme der Humangenetik, pp.52-125, 1959.
DOI : 10.1007/978-3-642-94744-5_2

E. Beutler, Study of glucose-6-phosphate dehydrogenase: History and molecular biology, American Journal of Hematology, vol.7, issue.1, pp.53-61, 1993.
DOI : 10.1002/ajh.2830420111

M. Oscarson, Pharmacogenetics of Drug Metabolising Enzymes: Importance for Personalised Medicine, Clinical Chemistry and Laboratory Medicine, vol.41, issue.4, pp.573-80, 2003.
DOI : 10.1515/CCLM.2003.087

;. Allorge and . Loriot, La pharmacogénétique ou la promesse d'une médecine personnalisée : variations du métabolisme et du transport des médicaments, Ann Biol Clin, vol.62, pp.499-511, 2004.

L. Becquemont, Pharmacogenomics of adverse drug reactions: practical applications and perspectives, Pharmacogenomics, vol.10, issue.6, pp.961-970, 1993.
DOI : 10.2217/pgs.09.37

V. Moreau, M. Siguret, and . Loriot, Antivitamines K??: pharmacologie et pharmacog??n??tique, EMC - Biologie m??dicale, vol.6, issue.2, 2011.
DOI : 10.1016/S2211-9698(11)71437-6

E. Morgan, K. Goralski, M. Piquette-miller, K. Renton, G. Robertson et al., Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer, Drug Metabolism and Disposition, vol.36, issue.2, pp.205-221, 2008.
DOI : 10.1124/dmd.107.018747

J. Robert, Pharmacogenetics and pharmacogenomics, 2006.

A. Brambila-tapia, MDR1 (ABCB1) polymorphisms: functional effects and clinical implications, Rev Invest Clin, vol.65, issue.5, pp.445-54, 2013.

C. Keyser, The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam Study Nicolas Picard, Différents types d'études en pharmacogénétique, Pharmacogenet Genomics, 1922.

M. Beaune and . Loriot, Bases mol??culaires de la susceptibilit?? aux x??nobiotiques : aspects m??taboliques., m??decine/sciences, vol.16, issue.10
DOI : 10.4267/10608/1524

E. Bates, W. Lau, and D. Angiolillo, Clopidogrel???Drug Interactions, Journal of the American College of Cardiology, vol.57, issue.11, pp.1251-126, 2011.
DOI : 10.1016/j.jacc.2010.11.024

P. Aigueperse, M. Gourmelon, and . Souidi, Cytochromes P450: xenobiotic metabolism,regulation and clinical importance; revue générale, Ann Biol Clin, vol.64, issue.6, pp.535-583, 2006.

J. Brockmoller, J. Kirchheiner, C. Meisel, and I. Roots, Pharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment, Pharmacogenomics, vol.1, issue.2, pp.125-51, 2000.
DOI : 10.1517/14622416.1.2.125

L. Nieuweboer, A. Clarke, S. Charles, K. De-graan, A. Haufroid et al., CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin, Pharmacogenomics, vol.14, issue.2, pp.137-186, 2013.

C. Xu, C. Li, and A. Kong, Induction of phase I, II and III drug metabolism/transport by xenobiotics, Archives of Pharmacal Research, vol.182, issue.481, pp.249-68, 2005.
DOI : 10.1007/BF02977789

E. Morgan, K. Goralski, M. Piquette-miller, K. Renton, G. Robertson et al., Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer, Drug Metabolism and Disposition, vol.36, issue.2, pp.205-221, 2008.
DOI : 10.1124/dmd.107.018747

S. Gardiner and E. Begg, Pharmacogenetics, Drug-Metabolizing Enzymes, and Clinical Practice, Pharmacological Reviews, vol.58, issue.3, pp.521-90, 2006.
DOI : 10.1124/pr.58.3.6

D. W. Nebert and E. Bingham, Pharmacogenomics: out of the lab and into the community, Trends in Biotechnology, vol.19, issue.12, pp.519-523, 2001.
DOI : 10.1016/S0167-7799(01)01805-4

U. Meyer, Genotype or phenotype: the definition of a pharmacogenetic polymorphism, Pharmacogenetics, vol.1, issue.2, pp.66-73, 1991.
DOI : 10.1097/00008571-199111000-00002

A. Daly, Development of analytical technology in pharmacogenetic research, Naunyn-Schmiedeberg's Archives of Pharmacology, vol.369, issue.1, pp.133-173, 2004.
DOI : 10.1007/s00210-003-0794-4

A. Gaedigk, Interethnic differences of drug-metabolizing enzymes, Int. Journal of Clinical Pharmacology and Therapeutics, vol.38, issue.02, pp.61-69, 2000.
DOI : 10.5414/CPP38061

L. Becquemont, A. Alfirevic, U. Amstutz, H. Brauch, E. Jacqz-aigrain et al., Practical recommendations for pharmacogenomics-based prescription, ESF-UB Conference onPharmacogenetics and Pharmacogenomics, pp.113-137, 2010.
DOI : 10.2217/pgs.10.147

K. Brøsen, Some Aspects of Genetic Polymorphism in the Biotransformation of Antidepressants, Th??rapie, vol.59, issue.1, 2004.
DOI : 10.2515/therapie:2004003

T. Yasumori, K. Nagata, S. K. Yang, L. S. Chen, N. Murayama et al., Cytochrome P450 mediated metabolism of diazepam in human and rat: involvement of human CYP2C in N-demethylation in the substrate concentration-dependent manner, Pharmacogenetics, vol.3, issue.6, 1993.
DOI : 10.1097/00008571-199312000-00003

S. M. Morais, G. R. Wilkinson, J. Blaisdell, K. Nakamura, and U. Meyer, The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans, Goldstein J A in The Journal of biological chemistry, 1994.

L. Xue-qing, A. Tommy, B. , and A. Marie, Weidolf Lars Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug metabolism and disposition: the biological fate of chemicals, 2004.

B. Jean-sébastien, V. Alessandra, A. Eric, R. Michel, G. Véronique et al., Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects, Blood, 2006.

J. Michael, . Dolton, J. Andrew, and . Mclachlan, Clinical importance of the CYP2C19*17 variant allele for voriconazole, Br J Clin Pharmacol, 2011.

T. S. Blaisdell, J. A. Goldstein, and J. , Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs, Journal of biochemical and molecular toxicology, 1999.

A. Neena, S. , H. Mark, A. , A. Elliott et al., AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents, Journal of the American College of Cardiology, 2010.